THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Abdulrafeh Naqash to Drug Administration Schedule

Back to Details
This is a "connection" page, showing publications Abdulrafeh Naqash has written about Drug Administration Schedule.
Abdulrafeh Naqash
Connection Strength
0.090
Drug Administration Schedule
  1. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844.
    View in: PubMed
    Score: 0.045
  2. Considerations for treatment duration in responders to immune checkpoint inhibitors. J Immunother Cancer. 2021 03; 9(3).
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES